<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tigecycline: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tigecycline: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tigecycline: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11448" href="/d/html/11448.html" rel="external">see "Tigecycline: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13076" href="/d/html/13076.html" rel="external">see "Tigecycline: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F22813605"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Mortality: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increase in all-cause mortality has been observed in a meta-analysis of phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% confidence interval [CI], 0.1 to 1.2) has not been established. Tigecycline should be reserved for use in situations when alternative treatments are not suitable.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F786537"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tygacil</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868681"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tygacil</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F786540"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Glycylcycline</li></ul></div>
<div class="block doa drugH1Div" id="F786577"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Given the increased mortality risk associated with tigecycline, reserve for use in situations when alternative treatments are not suitable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83e0ebe8-b935-4f5a-a26d-c059d314bdfc">
<i>Acinetobacter baumannii</i> infection, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Acinetobacter baumannii</i> infection, multidrug-resistant (off-label use): IV: </b>200 mg once, then 100 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30235740','lexi-content-ref-24887101','lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30235740','lexi-content-ref-24887101','lexi-content-ref-34864936'])">Ref</a></span>). For mild infection, may use as monotherapy (alternative agent); for moderate to severe infection, administer as part of an appropriate combination regimen.<b> Note:</b> Not recommended for urinary tract infection or as monotherapy for bloodstream infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for routine empiric use. Reserve use for patients with or at risk for certain multidrug-resistant organisms (eg, <i>K. pneumoniae</i> carbapenemase-producing Enterobacteriaceae, <i>Acinetobacter baumannii</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>100 mg once, then 50 mg every 12 hours; some experts suggest 200 mg once, then 100 mg every 12 hours for complicated infection (ie, with abscess or involving the peritoneum) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>). Some experts use as part of an appropriate combination regimen for certain resistant organisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Quale.1','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Quale.1','lexi-content-ref-28085573'])">Ref</a></span>). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (alternative agent for patients unable to tolerate beta-lactams or fluoroquinolones):</b> Inpatients without risk factors for <i>Pseudomonas aeruginosa</i>; not recommended for routine empiric use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg as a single dose, then 50 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18508226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18508226'])">Ref</a></span>). Total duration (which may include oral step-down therapy) is a minimum of 5 days; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-File.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-File.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aead4d70-fac5-4827-80b6-3ea6221522e2">Skin/skin structure infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin/skin structure infection, complicated:</b>
<b>IV:</b> Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dc8c99e-5200-48dc-a3c4-2ab11d9c2d8d">
<i>Stenotrophomonas maltophilia</i> infection, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Stenotrophomonas maltophilia</i> infection, multidrug-resistant (alternative agent) (off-label use): IV:</b> 200 mg once, then 100 mg every 12 hours. For mild infection, may use as monotherapy; for moderate to severe infection, administer as part of an appropriate combination regimen.<b> Note:</b> Not recommended for urinary tract infection or as monotherapy for bloodstream infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991810"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21953572','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21953572','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21953572','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21953572','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DOR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DOR.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989086"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">Severe hepatic impairment (Child-Pugh class C): Initial: 100 mg single dose; Maintenance: 25 mg every 12 hours.</p></div>
<div class="block doe drugH1Div" id="F786578"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F22813606"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13076" href="/d/html/13076.html" rel="external">see "Tigecycline: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, bacterial infection:</b> Limited data available: <b>Note:</b> Use should be reserved for situations when no effective alternative therapy is available and when benefits are expected to outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>). Duration of therapy dependent on severity and site of infection and response to therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;8 years: Reported dosing variable: <b>Note: </b>Use in in patients &lt;8 years is not recommended due to adverse effects on tooth development and uncertain dosing; however, use has been described in scenarios where alternative options were unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36196509','lexi-content-ref-31627248','lexi-content-ref-27000866','lexi-content-ref-30051224','lexi-content-ref-30008076','lexi-content-ref-28572073','lexi-content-ref-27381360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36196509','lexi-content-ref-31627248','lexi-content-ref-27000866','lexi-content-ref-30051224','lexi-content-ref-30008076','lexi-content-ref-28572073','lexi-content-ref-27381360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 1.5 to 2 mg/kg loading dose once, then 1 to 2 mg/kg/dose every 12 hours; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31627248','lexi-content-ref-27000866','lexi-content-ref-30051224','lexi-content-ref-29614915','lexi-content-ref-30125690','lexi-content-ref-30008076','lexi-content-ref-27381360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31627248','lexi-content-ref-27000866','lexi-content-ref-30051224','lexi-content-ref-29614915','lexi-content-ref-30125690','lexi-content-ref-30008076','lexi-content-ref-27381360'])">Ref</a></span>). <b>Note:</b> Higher loading doses of up to 4 mg/kg/dose have also been reported to treat multidrug resistant gram-negative bacteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27000866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27000866'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years and Adolescents: IV: 1.5 to 2 mg/kg loading dose once, then 1.2 to 2 mg/kg/dose every 12 hours; usual maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36196509','lexi-content-ref-27000866','lexi-content-ref-30051224','lexi-content-ref-22249106','lexi-content-ref-30008076','lexi-content-ref-27381360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36196509','lexi-content-ref-27000866','lexi-content-ref-30051224','lexi-content-ref-22249106','lexi-content-ref-30008076','lexi-content-ref-27381360'])">Ref</a></span>). A higher dose (4 mg/kg loading dose [maximum dose: 200 mg/dose], followed by 2 to 3.2 mg/kg/dose [maximum dose: 100 mg/dose] every 12 hours) has been suggested to mimic high-dose therapy used in adults, particularly for infections caused by carbapenem-resistant <i>Enterobacterales</i> infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31872226','lexi-content-ref-27000866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31872226','lexi-content-ref-27000866'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12b4d1cd-4b70-4386-91ff-806e2e485aef">Mycobacterial infection, nontuberculous; pulmonary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial infection, nontuberculous; pulmonary<b>: </b></b>Limited data available: <b>Note:</b> Use as part of an appropriate combination regimen; typically treat ≥12 months after culture conversion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 8 to &lt;12 years: IV: 1.2 mg/kg/dose every 12 hours; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077618','lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077618','lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV: 100 mg loading dose once, followed by 50 mg every 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077618','lexi-content-ref-29054853','lexi-content-ref-26666259','lexi-content-ref-24633206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077618','lexi-content-ref-29054853','lexi-content-ref-26666259','lexi-content-ref-24633206'])">Ref</a></span>). <b>Note: </b>A reduced dosage regimen of 50 mg every 24 hours or 25 mg every 12 to 24 hours may be considered in patients who do not tolerate higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31160063','lexi-content-ref-24633206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31160063','lexi-content-ref-24633206'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192753"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, no dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Poorly dialyzed. There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, no dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51192754"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. In adult patients with mild to moderate impairment (Child-Pugh class A or B), no dosage adjustment necessary; for severe hepatic impairment (Child Pugh class C), dosing adjustment is suggested.</p></div>
<div class="block adr drugH1Div" id="F786553"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (12%), nausea (24% to 35%), vomiting (16% to 20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Phlebitis (3%), septic shock, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia, hypoglycemia, hyponatremia (2%), increased amylase (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (6%), abnormal stools, anorexia, dysgeusia, dyspepsia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Leukorrhea, vaginitis, vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (5%), eosinophilia, hypoproteinemia (5%), increased INR, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (2%), increased serum alanine aminotransferase (5%), increased serum alkaline phosphatase (3%), increased serum aspartate aminotransferase (4%), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (2%), infection (7%), sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site, injection site phlebitis, injection site reaction, pain at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness (3%), headache (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (3%), increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Severe dermatological reaction, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, <i>Clostridioides difficile</i> associated diarrhea, enamel hypoplasia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (including rectal bleeding and ecchymoses [Ciu 2019]), hypofibrinogenemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, intrahepatic cholestasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, nonimmune anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F786549"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to tigecycline or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to tetracycline class of antibiotics</p></div>
<div class="block war drugH1Div" id="F786550"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/Hypersensitivity reactions: May cause life-threatening anaphylaxis. Due to structural similarity with tetracyclines, avoid use in patients with known hypersensitivity to tetracycline-class antibiotics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antianabolic effects: May be associated with antianabolic effects observed with the tetracycline class (including increased BUN, azotemia, acidosis, and hyperphosphatemia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Coagulopathy: May be associated with abnormalities of blood coagulation parameters, including prolongation of PT and aPTT and decreased fibrinogen that may be dose- and/or time-dependent, in particular in patients with renal and hepatic impairment; discontinue use when suspected (Cui 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Abnormal liver function tests (increased total bilirubin, prothrombin time, transaminases) have been reported. Isolated cases of significant hepatic dysfunction and hepatic failure have occurred. Closely monitor for worsening hepatic function in patients who develop abnormal liver function tests during therapy. Adverse hepatic effects may occur after drug discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Acute pancreatitis (including fatalities) has been reported, including patients without known risk factors; discontinue use when suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: May be associated with photosensitivity due to structural similarities with tetracyclines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudotumor cerebri: May be associated with pseudotumor cerebri due to structural similarities with tetracyclines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Treatment-related mortality: <b>[US Boxed Warning]: In a meta analysis of Phase 3 and 4 clinical trials, an increase in all-cause mortality has been observed in tigecycline-treated patients versus comparator-treated patients. The cause of the mortality risk difference (0.6% [95% CI 0.1, 1.2]) has not been established. Use should be reserved for situations in which alternative treatments are not suitable.</b> In general, deaths were the result of worsening infection, complications of infection, or underlying comorbidity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-abdominal infections: Avoid use as monotherapy for patients with intestinal perforation (in the small sample of available cases, sepsis/septic shock occurred more frequently than patients treated with imipenem/cilastatin comparator).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Safety and efficacy in children and adolescents &lt;18 years of age have not been established due to increased mortality observed in trials of adult patients. Use only if no alternative antibiotics are available. Because of potential effects on tooth development (yellow-gray-brown discoloration), use in patients &lt;8 years of age is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not use for diabetic foot infections; non-inferiority was not demonstrated in studies. Do not use for healthcare-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP); increased mortality and decreased efficacy have been reported in HAP and VAP trials.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F58745512"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Tigecycline use in individuals &lt;8 years of age may result in permanent tooth discoloration (yellow, gray, or brown) and/or enamel hypoplasia. Specific incidence of tooth discoloration following tigecycline treatment in patients &lt;8 years is unknown; with tetracyclines in general, discoloration is more common with long-term use but may also be observed with repeated, short courses. While doxycycline courses up to 21 days have been considered acceptable and low-risk for discoloration, doxycyclines calcium-binding capacity is lower than that of tetracycline; tigecyclines calcium-binding capacity is not known (Red Book [AAP 2021]; Stultz 2019; Zhu 2021). Therefore, doxycycline use recommendations cannot be applied to tigecycline. In a dental evaluation of 12 patients who had previously received tigecycline while &lt;8 years old, 2 patients (16.7%) developed mild tooth discoloration after receiving tigecycline for ≥19 days; definitive causation was not able to be assessed (Zhu 2021). In a retrospective chart review of 91 pediatric patients aged 7 months to 17.5 years who received tigecycline for a median of 12 days (range: 3 to 27 days), no tooth discoloration was documented during 2 years of follow-up for any patient; however, study methods limit conclusions (Aslan 2022). Tooth discoloration has been reported in a 9-year-old who received tigecycline for 47 days (Lin 2018).</p></div>
<div class="block foc drugH1Div" id="F786583"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tygacil: 50 mg (1 ea) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F786539"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324124"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Tigecycline Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $124.80 - $187.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Tygacil Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $120.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868682"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tygacil: 50 mg (1 ea) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F786581"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse over 30 to 60 minutes through dedicated line or via Y-site. If the same IV line is used for sequential infusion of several drugs, flush line with NS, D5W, or LR before and after tigecycline administration.</p></div>
<div class="block admp drugH1Div" id="F52614141"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Infuse over 30 to 60 minutes through dedicated line or via Y-site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31627248','lexi-content-ref-29614915','lexi-content-ref-22249106','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31627248','lexi-content-ref-29614915','lexi-content-ref-22249106','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F786544"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b> Treatment of complicated intra-abdominal infections in patients ≥18 years of age caused by <i>Citrobacter freundii</i>, <i>Enterobacter cloacae</i>, <i>Escherichia coli</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates), <i>Staphylococcus aureus</i> (methicillin-susceptible and methicillin-resistant isolates), <i>Streptococcus anginosus</i> group (includes <i>S. anginosus</i>, <i>Streptococcus intermedius</i>, and <i>Streptococcus constellatus</i>), <i>Bacteroides fragilis</i>, <i>Bacteroides thetaiotaomicron</i>, <i>Bacteroides uniformis</i>, <i>Bacteroides vulgatus</i>, <i>Clostridium perfringens</i>, and <i>Peptostreptococcus micros</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community acquired:</b> Treatment of community-acquired bacterial pneumonia in patients ≥18 years of age caused by <i>Streptococcus pneumoniae</i> (penicillin-susceptible isolates), including cases with concurrent bacteremia, <i>Haemophilus influenzae</i>, and <i>Legionella pneumophila</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infections, complicated:</b> Treatment of complicated skin and skin structure infections in patients ≥18 years of age caused by <i>E. coli</i>, <i>E. faecalis</i> (vancomycin-susceptible isolates), <i>S. aureus</i> (methicillin-susceptible and methicillin-resistant isolates), <i>Streptococcus agalactiae</i>, <i>S. anginosus</i> group (includes <i>S. anginosus</i>, <i>S. intermedius</i>, and <i>S. constellatus</i>), <i>Streptococcus pyogenes</i>, <i>E. cloacae</i>, <i>K. pneumoniae</i>, and <i>B. fragilis</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Limitations of use:</b> Not indicated for treatment of diabetic foot infections; a clinical trial failed to demonstrate noninferiority of tigecycline for treatment of diabetic foot infections. Not indicated for treatment of hospital-acquired or ventilator-associated pneumonia; greater mortality and decreased efficacy were reported in tigecycline-treated patients in a comparative clinical trial.</p></div>
<div class="block off-label drugH1Div" id="F58523274"><span class="drugH1">Use: Off-Label: Adult</span><p>Acinetobacter baumannii infection, multidrug-resistant; Stenotrophomonas maltophilia infection</p></div>
<div class="block cyt drugH1Div" id="F13300141"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F786559"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Tetracyclines may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Tetracyclines may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Tigecycline may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Tigecycline may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F786546"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tigecycline crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term use or short-term repeated exposure. In addition, tetracycline use has been associated with reversible retardation of skeletal development and reduced bone growth.</p></div>
<div class="block brc drugH1Div" id="F786548"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tigecycline is found in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Although oral bioavailability is low and exposure to the breastfed infant is expected to be limited, the manufacturer does not recommend breastfeeding if maternal therapy is required for &gt;3 weeks due to the potential risk of tooth discoloration and inhibition of bone growth in the infant. The manufacturer suggests temporarily pumping and discarding breast milk during therapy and for 9 days after the last maternal tigecycline dose to minimize exposure to the breastfed infant. In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea. Use of medications other than tetracyclines should be used when possible (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F46311140"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hepatic function (periodically); coagulation parameters (including aPTT, PTT, fibrinogen) at baseline and regularly during therapy. Observe for signs and symptoms of anaphylaxis during administration.</p></div>
<div class="block pha drugH1Div" id="F786567"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A glycylcycline antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, thereby, inhibiting protein synthesis. Generally considered bacteriostatic; however, bactericidal activity has been demonstrated against isolates of <i>S. pneumoniae</i> and <i>L. pneumophila</i>. Tigecycline is a derivative of minocycline (9-t-butylglycylamido minocycline), and while not classified as a tetracycline, it may share some class-associated adverse effects. Tigecycline has demonstrated activity against a variety of gram-positive and -negative bacterial pathogens including methicillin-resistant staphylococci.</p></div>
<div class="block phk drugH1Div" id="F786569"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">Distribution: V<sub>d</sub>: Children (8 to 11 years): 2.84 L/kg (range: 0.397 to 11.2 L/kg) (Purdy 2012); Adults: 7 to 9 L/kg; extensive tissue distribution; distributes into gallbladder, lung, and colon </p>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">Protein binding: 71% to 89%</p>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">Metabolism: Hepatic, via glucuronidation, N-acetylation, and epimerization to several metabolites, each &lt;10% of the dose</p>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">Half-life elimination: Single dose: 27 hours; following multiple doses: 42 hours;  increased by 23% in moderate hepatic impairment and 43% in severe hepatic impairment</p>
<p style="text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;">Excretion: Feces (59%, primarily as unchanged drug); urine (33%, with 22% of the total dose as unchanged drug)</p>
<p style="text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;">Clearance: Reduced by 25% in patient with moderate hepatic impairment and 55% in severe hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539958"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tigecyclin mylan | Tigecyclin sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Tigacil | Widebac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tigecyclin sandoz | Tigecycline accord | Tygacil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline sandoz | Tygacil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Kalyme | Tigeciclina | Tygacil | Tyzel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Expociclina | Geclix | Linicetil | Tigecic | Tigeciclina | Tigevitae | Tiglex | Tygacil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline mylan | Tigecycline olikla | Tigecycline sandoz | Tigecycline teva | Tygacil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Tigecyclin hexal | Tigecyclin mylan | Tigecyclin ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Tigeciclina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tigeciclina accord | Tigeciclina mylan | Tigeciclina normon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline mylan | Tygacil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Digazor | Tygacil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline teva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Algeline | Cachtin | Critig | Emtig | Het tg | Innocycline | Tigaphar | Tigebax | Tigecross | Tigene | Tigeniche | Tigeo | Tigerad | Tigercin | Tigeshan | Tigetuf | Tigi | Tigitrust | Tiziren | Tygacil | Tygaray | Zutig</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tigeciclina | Tigeciclina mylan pharma</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Tagix | Tygacil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Tigebax | Tygacil | Tylin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Penmix tigecycline | Tygacil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Tagix | Tygacil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Gecifhil | Grexyl | Linicetil | Treprex | Tygacil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Tigar | Tygacil</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline juno | Tygacil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Tigevitae | Tigilyn | Zomiprerin pd</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Tagagy | Tegecin | Tigacel | Tigasafe | Tigcil | Tigelin | Tigemark | Tigewel | Tigowin | Tilane | Tygacil | Tygin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline mylan | Tigecycline sandoz</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Tigeciclina mylan | Tigeciclina tecnigen | Tigeciclina teva | Tygacil</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Spemicina | Tigeciclina cellofarm | Tigeciclina dasanti | Tigeciclina demotek | Tigeciclina imedic | Tygacil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tigeciclina atb | Tigeciclina mylan | Tygacil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Tigacil | Tigecycline j | Tigecycline psk</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline accord | Tigecycline mylan | Tygacil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tigeciklin sandoz | Tygacil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline sandoz | Tygacil</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bacticil | Capessa | Tyzel</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Tygacil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mrsacin | Tigecid | Tigeject | Tigenex | Tigesil liyo | Tybicid | Tygepol | Tygex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tigelin | Tygacil</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Tigecycline vista</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Tygacil | Tygelina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rubicil | Tacyl | Tigebax | Tigecycline accord | Tygacil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36196509">
<a name="36196509"></a>Aslan K, Kiliç Ö, Kiral E, Bozan G, Bör Ö, Dinleyici EÇ. Clinical and laboratory responses to tigecycline in children. <i>J Clin Pharm Ther</i>. 2022;47(10):1585-1590. doi:10.1111/jcpt.13708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/36196509/pubmed" id="36196509" target="_blank">36196509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18990531">
<a name="18990531"></a>Bergallo C, Jasovich A, Teglia O, et al, “Safety and Efficacy of Intravenous Tigecycline in Treatment of Community-Acquired Pneumonia: Results From a Double-Blind Randomized Phase 3 Comparison Study With Levofloxacin,” <i>Diagn Microbiol Infect Dis</i>, 2009, 63(1):52-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/18990531/pubmed" id="18990531" target="_blank">18990531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558639">
<a name="30558639"></a>Broeker A, Wicha SG, Dorn C, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. <i>Crit Care</i>. 2018;22(1):341. doi:10.1186/s13054-018-2278-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/30558639/pubmed" id="30558639" target="_blank">30558639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31627248">
<a name="31627248"></a>Chen F, Shen C, Pang X, et al. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: a retrospective study. <i>Transpl Infect Dis</i>. 2020;22(1):e13199. doi:10.1111/tid.13199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/31627248/pubmed" id="31627248" target="_blank">31627248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30235740">
<a name="30235740"></a>Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. <i>Medicine (Baltimore)</i>. 2018;97(38):e12467. doi:10.1097/MD.0000000000012467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/30235740/pubmed" id="30235740" target="_blank">30235740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31872226">
<a name="31872226"></a>Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. <i>J Pediatric Infect Dis Soc</i>. 2020;9(1):56-66. doi:10.1093/jpids/piz085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/31872226/pubmed" id="31872226" target="_blank">31872226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15885987">
<a name="15885987"></a>Conte JE Jr, Golden JA, Kelly MG, et al, "Steady-State Serum and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Tigecycline," <i>Int J Antimicrob Agents</i>, 2005, 25(6):523-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/15885987/pubmed" id="15885987" target="_blank">15885987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31713108">
<a name="31713108"></a>Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. <i>Int J Clin Pharm</i>. 2019;41(6):1408‐1413. doi:10.1007/s11096-019-00912-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/31713108/pubmed" id="31713108" target="_blank">31713108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19036672">
<a name="19036672"></a>Dartois N, Castaing N, Gandjini H, et al, “Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience,” <i>J Chemother</i>, 2008, 20(Suppl 1):28-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/19036672/pubmed" id="19036672" target="_blank">19036672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24887101">
<a name="24887101"></a>De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. <i>Crit Care</i>. 2014;18(3):R90. doi:10.1186/cc13858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/24887101/pubmed" id="24887101" target="_blank">24887101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DOR.1">
<a name="DOR.1"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.; id: Expert.DOR</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax.</i> 2016;71(suppl 1):i1–i22. doi:10.1136/thoraxjnl-2015-207360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2084658">
<a name="2084658"></a>Freire AT, Melnyk V, Kim MJ, et al; 311 Study Group. Comparison of tigecycline with imipenem/ cilastatin for the treatment of hospital-acquired pneumonia. <i>Diagn Microbiol Infect</i>
<i>Dis.</i> 2010;68(2):140-151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/2084658/pubmed" id="2084658" target="_blank">2084658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15555879">
<a name="15555879"></a>Fritsche TR and Jones RN, "Antimicrobial Activity of Tigecycline (GAR-936) Tested Against 3498 Recent Isolates of <i>Staphylococcus aureus</i> Recovered From Nosocomial and Community-Acquired Infections," <i>Int J Antimicrob Agents</i>, 2004, 24(6):567-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/15555879/pubmed" id="15555879" target="_blank">15555879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci</i>. 2018;25(1):3-16. doi:10.1002/jhbp.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1‐ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27000866">
<a name="27000866"></a>Iosifidis E, Violaki A, Michalopoulou E, et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. <i>J Pediatric Infect Dis Soc</i>. 2017;6(2):123-128. doi:10.1093/jpids/piw009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/27000866/pubmed" id="27000866" target="_blank">27000866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14982803">
<a name="14982803"></a>Jacobus NV, McDermott LA, Ruthazer R, et al, "In Vitro Activities of Tigecycline Against the <i>Bacteroides fragilis</i> Group," <i>Antimicrob Agents Chemother</i>, 2004, 48(3):1034-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/14982803/pubmed" id="14982803" target="_blank">14982803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21953572">
<a name="21953572"></a>Korth-Bradley JM, Troy SM, Matschke K, Muralidharan G, Fruncillo RJ, Speth JL, Raible DG. Tigecycline pharmacokinetics in subjects with various degrees of renal function. <i>J Clin Pharmacol</i>. 2012;52(9):1379-1387. doi:10.1177/0091270011416938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/21953572/pubmed" id="21953572" target="_blank">21953572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29614915">
<a name="29614915"></a>Lin S, Liang L, Zhang C, Ye S. Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia. <i>J Int Med Res</i>. 2020;48(1):300060518760435. doi:10.1177/0300060518760435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/29614915/pubmed" id="29614915" target="_blank">29614915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30051224">
<a name="30051224"></a>Lin S, Zhang C, Ye S. Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies. <i>Int J Clin Pharm</i>. 2018;40(5):1030-1036. doi: 10.1007/s11096-018-0690-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/30051224/pubmed" id="30051224" target="_blank">30051224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. <i>Clin Infect Dis</i>. 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077618">
<a name="31077618"></a>Longworth SA, Daly JS; AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients -Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13588. doi: 10.1111/ctr.13588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/31077618/pubmed" id="31077618" target="_blank">31077618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18354105">
<a name="18354105"></a>Munoz-Price LS and Weinstein RA, “Acinetobacter Infection,” <i>N Engl J Med</i>, 2008, 358(12):1271-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/18354105/pubmed" id="18354105" target="_blank">18354105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616299">
<a name="15616299"></a>Muralidharan G, Micalizzi M, Speth J, et al, "Pharmacokinetics of Tigecycline After Single and Multiple Doses in Healthy Subjects," <i>Antimicrob Agents Chemother</i>, 2005, 49(1):220-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/15616299/pubmed" id="15616299" target="_blank">15616299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814687">
<a name="20814687"></a>Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. <i>Arch Gynecol Obstet</i>. 2011;283(1):7-18. doi: 10.1007/s00404-010-1646-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/20814687/pubmed" id="20814687" target="_blank">20814687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17082201">
<a name="17082201"></a>Peleg AY, Potoski BA, Rea R, et al, “<i>Acinetobacter baumannii</i> Bloodstream Infection While Receiving Tigecycline: A Cautionary Report,” <i>J Antimicrobic Chemother</i>, 2007, 59(1):128-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/17082201/pubmed" id="17082201" target="_blank">17082201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22249106">
<a name="22249106"></a>Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. <i>Clinical Therapeutics</i>. 2012;34(2): 496-507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/22249106/pubmed" id="22249106" target="_blank">22249106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quale.1">
<a name="Quale.1"></a>Quale J, Spelman D. Overview of carbapenemase-producing gram-negative bacilli. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23357775">
<a name="23357775"></a>Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. <i>Antimicrob Agents Chemother</i>. 2013;57(4):1756-1762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/23357775/pubmed" id="23357775" target="_blank">23357775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16863487">
<a name="16863487"></a>Rose WE and Rybak MJ, “Tigecycline: First of a New Class of Antimicrobial Agents,” <i>Pharmacotherapy</i>, 2006, 26(8):1099–110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/16863487/pubmed" id="16863487" target="_blank">16863487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31160063">
<a name="31160063"></a>Shulha JA, Escalante P, Wilson JW. Pharmacotherapy approaches in nontuberculous mycobacteria infections. <i>Mayo Clin Proc</i>. 2019;94(8):1567-1581. doi: 10.1016/j.mayocp.2018.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/31160063/pubmed" id="31160063" target="_blank">31160063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30125690">
<a name="30125690"></a>Song Y, Hu L, Shu Q, et al. Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery. <i>Int J Infect Dis</i>. 2018;75:82-88. doi:10.1016/j.ijid.2018.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/30125690/pubmed" id="30125690" target="_blank">30125690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31280586">
<a name="31280586"></a>Stultz JS, Eiland LS. Doxycycline and tooth discoloration in children: changing of recommendations based on evidence of safety. <i>Ann Pharmacother</i>. 2019;53(11):1162-1166. doi:10.1177/1060028019863796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/31280586/pubmed" id="31280586" target="_blank">31280586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. <i>Clin Infect Dis</i>. 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18508226">
<a name="18508226"></a>Tanaseanu C, Bergallo C, Teglia O, et al, “Integrated Results of 2 Phase 3 Studies Comparing Tigecycline and Levofloxacin in Community-Acquired Pneumonia,” <i>Diagn Microbiol Infect Dis</i>, 2008, 61(3):329-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/18508226/pubmed" id="18508226" target="_blank">18508226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19740418">
<a name="19740418"></a>Tanaseanu C, Milutinovic S, Calistru PI, et al; 313 Study Group. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. <i>BMC Pulm Med</i>. 2009;9:44. doi:10.1186/1471-2466-9-44<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/19740418/pubmed" id="19740418" target="_blank">19740418</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tygacil (tigecycline) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc; May 2021.</div>
</li>
<li>
<div class="reference">
                  Tygacil (tigecycline) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc; July 2020.</div>
</li>
<li>
<div class="reference">
                  Tygacil (tigecycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tygacil.4">
<a name="Tygacil.4"></a>Tygacil (tigecycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; July 2023.</div>
</li>
<li>
<div class="reference">
                  Tygacil (tigecycline) [summary of product characteristics]. Bruxelles, Belgium: Pfizer Europe MA EEIG; February 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline</a>. Published September 27, 2013. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24633206">
<a name="24633206"></a>Wallace RJ Jr, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. <i>J Antimicrob Chemother</i>. 2014;69(7):1945-1953. doi:10.1093/jac/dku062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/24633206/pubmed" id="24633206" target="_blank">24633206</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO); UNICEF. Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30008076">
<a name="30008076"></a>Ye S, Zhang C, Lin S. Preliminary experience with tigecycline treatment for severe infection in children. <i>Eur J Pediatr</i>. 2018;177(10):1489-1496. doi: 10.1007/s00431-018-3208-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/30008076/pubmed" id="30008076" target="_blank">30008076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28572073">
<a name="28572073"></a>Zeng J, Zhang L, Gao M, et al. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia. <i>Int J Infect Dis</i>. 2017;61:23-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/28572073/pubmed" id="28572073" target="_blank">28572073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32006240">
<a name="32006240"></a>Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. <i>Adv Ther</i>. 2020;37(3):1049-1064. doi:10.1007/s12325-020-01235-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/32006240/pubmed" id="32006240" target="_blank">32006240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14723559">
<a name="14723559"></a>Zhanel GG, Homenuik K, Nichol K, et al, "The Glycylcyclines: A Comparative Review With the Tetracyclines," <i>Drugs</i>, 2004, 64(1):63-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/14723559/pubmed" id="14723559" target="_blank">14723559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34228549">
<a name="34228549"></a>Zhu Z, Yu Q, Qi G, et al. Tigecycline-induced tooth discoloration in children younger than eight tears. <i>Antimicrob Agents Chemother</i>. 2021;65(9):e0085421. doi: 10.1128/AAC.00854-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/34228549/pubmed" id="34228549" target="_blank">34228549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27381360">
<a name="27381360"></a>Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. <i>Acta Paediatr</i>. 2016;105(10):e480-484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/27381360/pubmed" id="27381360" target="_blank">27381360</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9458 Version 248.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
